The Generium MBC, one of the leading Russian developers and manufacturers of biotech products, is the first in Russia to implement the ambr automated platform to scale biotechnological processes. The system will accelerate the development and launch of new domestic biotech medicinal products.
New equipment will be used in the departments of cell biology and of process development of the Generium center. First, the cell line group experts obtain stable producers of future protein therapeutics in ambr
«In our laboratory, we choose the best from among the many thousands of clones of the parent cell, those that can consistently grow and multiply in bioreactors and the product of which has the required therapeutic properties," says Dmitry Poteryaev, Head of the Cell Biology Department. «This is a laborious process which is now largely automated by the ambr
After careful selection of stable cell lines for future biological products,
«The system facilitates economical, fast, and reliable laboratory development scaling to prepare for implementation in production," says Denis Feshin, Head of the Department of Process Development at the Generium center.
A total of over one hundred and fifty ambr systems manufactured by TAP Biosystems operate worldwide in leading pharmaceutical and